Measurement-based care versus standard care for major depression: A randomized controlled trial with blind raters

American Journal of Psychiatry

Volumn 172, Issue 10, 2015, Pages 1004-1013

  Guo, Tong ^{a,b,c,d,e,f,g}   Xiang, Yu Tao ^{a,b,c,d,e,f,g}   Xiao, Le ^{a,b,c,d,e,f,g}   Hu, Chang Qing ^{a,b,c,d,e,f,g}   Chiu, Helen F K ^{a,b,c,d,e,f,g}   Ungvari, Gabor S ^{a,b,c,d,e,f,g}   Correll, Christoph U ^{a,b,c,d,e,f,g}   Lai, Kelly Y C ^{a,b,c,d,e,f,g}   Feng, Lei ^{a,b,c,d,e,f,g}   Geng, Ying ^{a,b,c,d,e,f,g}   Feng, Yuan ^{a,b,c,d,e,f,g}   Wang, Gang ^{a,b,c,d,e,f,g}  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c University of Macau   (Macao)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; LORAZEPAM; MIRTAZAPINE; OXAZEPAM; PAROXETINE; ANTIDEPRESSANT AGENT; MIANSERIN;

ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT BASED CARE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYMPTOM; ANALOGS AND DERIVATIVES; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; CLINICAL DECISION-MAKING; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84942889000     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14050652     Document Type: Article

References (35)

1. Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-627
2. Rush AJ, Trivedi MH, Wisniewski SR, et al: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231-1242
3. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major d epressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105
4. Trivedi MH, Daly EJ: Measurement-based care for refractory depression: a clinical decisio n support model for clinical research and practice. Drug Alcohol Depend 2007; 88(suppl 2):S61-S71
5. Trivedi MH,Rush AJ,Crismon ML,et al Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project Arch Gen Psychiatry 2004 61 669-680
6. Crismon ML, Trivedi M, Pigott TA, et al: The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999; 60:142-15 6
7. Shon SP, CrismonML,TopracMG,et al: Mental health care from the public perspective: the Texas Medication Algorithm Project. J Clin Psychiatry 1999; 60(suppl 3):16-20, discussion 21
8. Adli M, Berghöfer A, Linden M, et al: Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Ps ychiatry 2002; 63:782-790
9. Adli M, Rush AJ, Möller HJ, et al: Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 2003; 36(suppl 3):S222-S229
10. Adli M, Bauer M, Rush AJ: Algorithms and collaborative-care systems for depression: are they effective and why?Asystematic review. Biol Psychiatry 2006; 59:1029-1038
11. Ricken R,Wiethoff K, Reinhold T, et al: Algorithm-guided treatment of depression reduces treatment costs: results from the randomized controlled German Algorithm Project (GAPII). J Affect Disord 2011; 134:249-256
12. Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
13. Trivedi MH: Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry 2009; 70(suppl 6):26-31
14. Bauer M, Pfennig A, Linden M, et al: Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 2009; 29:327-333
15. Wiethoff K, Bauer M, Baghai TC, et al: Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry 2010 71:1047-1054
16. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
17. Xie GR, Shen QJ: [Use of the Chinese version of the Hamilto n Rating Scale for Depression in general population and patients with major depression.] Chinese Journal of Nervous and Mental Diseases 1984; 10:346 (Chinese)
18. Bezchlibnyk-Butler KZ, Jeffries JJ: Clinical Handbook of Psychotropic Drugs, 11th ed. Toronto, Hogrefe and Huber, 2001
19. Chinese Medical Association: Guideline for the Prevention and Treatment of Psychiatric Disorders in China. Beijing, Chinese Medical Association, 2003
20. Holm KJ, Markham A Mirtazapine: a review of its use in major depression. Drugs 1999; 57:607-631
21. Rush AJ, Trivedi MH, Ibrahim HM, et al: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Cli nician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583
22. Liu J, Xiang YT, Wang G, et al: Psych ometric properties of the Chinese versions of the Quick Inventory of Depressive Symptomatology-Clinician Rating (C-QIDS-C) and Self-Report (C-QIDS-SR). J Affect Disord 2013; 147:421-424
23. Wisniewski SR, Ru sh AJ, Balasubramani GK, et al: Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006; 12:71-79
24. Trivedi MH, Rush AJ, Gaynes BN, et al: Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR D measurement-based care. Neuropsychopharmacology 2007; 32:2479-2489
25. Young RC, Biggs JT Ziegler VE, et al: A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133:429-435
26. Bridge JA,Iyengar S,Salary CB,et al Clinical response and r isk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-Analysis of randomized controlled trials JAMA 2007, 297, 1683-1696
27. Rush AJ, Kraemer HC, Sackeim HA , et al: Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31:1841-1853
28. Judd LL: Major depressive disorder: longitudinal symptomatic structure, relapse, and recovery. Acta Psychiatr Scand 2001; 104:81-83
29. Hollon SD, DeRubeis RJ, Fawcett J, et al: Effect of cognitive therapy with antidepressant medications vs antidepres sants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71:1157-1164
30. Keller MB, McCullough JP, Klein DN, et al: A comparison of n efazodone, the cognitive behavioral-Analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462-1470
31. Sussman N: Translating science into s ervice: lessons learned from the Sequenced Treatment Alternatives to Relieve Depression (STAR D) study. Prim Care Companion J Clin Psychiatry 2007; 9: 331-337
32. Xiang YT,YuX, SartoriusN, et al: Mental health in China: challenges and progress. Lancet 2012; 380:1715-1716
33. Rush AJ, Fava M, Wisniewski SR, et al: Sequenced Treatment Alternatives to Relieve Depression (STAR D): rationale and design. Control Clin Trials 2004; 25:119-142
34. Cipriani A, Furukawa TA, Salanti G, et al: Comparative efficacy a nd acceptability of 12 new-generation antidepressants: a multipletreatments meta-Analysis. Lancet 2009; 373:746-758
35. Ma X, Xiang YT, Cai ZJ, et al: Prevalence and socio-demographic correlates of major depressive episode in rural and urban areas of Beijing, China. J Affect Disord 2009; 115:323-330